Taming the PI3K team to hold inflammation and cancer at bay
- 31 May 2008
- journal article
- review article
- Published by Elsevier BV in Pharmacology & Therapeutics
- Vol. 118 (2), 192-205
- https://doi.org/10.1016/j.pharmthera.2008.02.004
Abstract
No abstract availableKeywords
This publication has 98 references indexed in Scilit:
- Negative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase γProceedings of the National Academy of Sciences of the United States of America, 2007
- A transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature, 2007
- Rare cancer-specific mutations in PIK3CA show gain of functionProceedings of the National Academy of Sciences of the United States of America, 2007
- Phosphoinositide 3-kinase γ/δ inhibition limits infarct size after myocardial ischemia/reperfusion injuryProceedings of the National Academy of Sciences of the United States of America, 2006
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006
- A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in gliomaCancer Cell, 2006
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin SignalingCell, 2006
- Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesisNature Reviews Cancer, 2006
- Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapyLeukemia, 2003
- Akt Enhances Mdm2-mediated Ubiquitination and Degradation of p53Published by Elsevier BV ,2002